SLC7A2作为肝细胞癌新的生物标志物研究

SLC7A2 as a new biomarker for hepatocellular carcinoma

目的:探讨SLC7A2基因作为肝细胞癌(HCC)患者潜在新的生物标志物前景。方法:利用肿瘤基因组图谱(TCGA)数据挖掘SLC7A2在HCC患者中的表达水平。采用Kaplan-Meier法、Cox回归分析法和列线图评价SLC7A2在HCC中的预后价值。结果:与正常肝组织相比,HCC组织SLC7A2表达显著降低(P<0.05)。SLC7A2低表达与血清中高AFP水平、血管浸润、残余肿瘤、复发和死亡显著相关(P<0.05)。Kaplan-Meier分析表明,SLC7A2的低表达与肝细胞癌的整体生存率(OS)显著相关(P=0.006),与无病生存期(DFI)无显著相关(P=0.09)。多因素分析进一步证实SLC7A2低表达是肝细胞癌患者OS的独立指标(P<0.05)。HCC中SLC7A2的表达下调基于DNA拷贝缺失和SLC7A2甲基化减少。结论:SLC7A2可作为HCC患者预后新的生物标志物和候选治疗靶点。

Objective:To exploring the prospect of SLC7A2 gene as a potential new biomarker in patients with hepatocellular carcinoma(HCC).Methods:The expression level of SLC7A2 in HCC patients was mined by TCGA data.The prognostic value of SLC7A2 in HCC was evaluated by Kaplan-Meier method,Cox regression analysis and line plot.Results:The SLC7A2 of hepatocellular carcinoma was significantly down-regulated compared with normal liver tissue(P<0.05).Low SLC7A2 expression was significantly associated with low serum AFP levels,vascular infiltration,residual tumor,recurrence,and death(P<0.05).Kaplan-Meier analysis showed that down-regulation of SLC7A2 was significantly associated with overall survival(OS)in hepatocellular carcinoma(P=0.006),but not with disease free interval(DFI,P=0.09).Multivariate analysis further confirmed SLC7A2 downregulation as an independent indicator of OS(P<0.05).SLC7A2 down-regulation mechanism expression in HCC was based on DNA copy deletion and reduced SLC7A2 methylation.Conclusion:SLC7A2 may be a prognostic biomarker and a candidate therapeutic target for hepatocellular carcinoma.